The pharmaceutical industry often justifies high drug prices by claiming that they create more innovation, but two recent studies find that drug costs and clinical benefit are often not related. More
Breaking down the flawed logic of "What do we have to lose?" when it comes to untested Covid-19 treatments. More
Many physicians see drug samples as a benefit, because they can give pills to patients who may not be able to afford the medication otherwise. But are these "free" samples really free? More
When it comes to dementia and Alzheimer's Disease, it appears that anxiety about cognitive decline is driving treatment decisions, rather than evidence. More
Is sunshine really the best disinfectant? Or do we need much more than transparency when it comes to financial conflicts of interest? More
It's a Lown Institute tradition to highlight pharma's fear-mongering on Halloween, and this year is no exception. More
The approval of a new gene therapy to treat spinal muscular atrophy has created a hot debate in the health policy world about whether or not the drug's $2.1 million price tag is too expensive or a fair price. More
Why the revolving door poses a serious problem for government agency regulation. More
As the powerful depression drug esketamine nearly FDA approval, some researchers are concerned that the approval would be lowering the bar for clinical evidence. More
Our willingness to turn a blind eye to the profiteering of biotech is a moral failing, writes Dr. Vikas Saini in a Commonhealth op-ed. More